These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10845224)

  • 21. Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters.
    Roeske JC; Chen GT; Atcher RW; Pelizzari CA; Rotmensch J; Haraf D; Montag A; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1990 Dec; 19(6):1539-48. PubMed ID: 2262379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model.
    Flynn AA; Green AJ; Boxer GM; Casey JL; Pedley RB; Begent RH
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):183-9. PubMed ID: 9989525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
    Sharkey RM; Goldenberg DM; Vagg R; Pawlyk D; Wong GY; Siegel JA; Murthy S; Levine GM; Izon D; Gascon P
    Cancer; 1994 Feb; 73(3 Suppl):864-77. PubMed ID: 8306272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.
    Breitz HB; Durham JS; Fisher DR; Weiden PL
    Cancer Res; 1995 Dec; 55(23 Suppl):5817s-5822s. PubMed ID: 7493352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution.
    Fujimori K; Fisher DR; Weinstein JN
    Cancer Res; 1991 Sep; 51(18):4821-7. PubMed ID: 1893374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts.
    Roberson PL; Yokoyama S; Rogers BE; Buchsbaum DJ
    Cancer Biother Radiopharm; 2003 Apr; 18(2):239-47. PubMed ID: 12804050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2.
    Yamamoto A; Sawada T; Yamashita Y; Nishihara T; Ho JJ; Kim Y; Chung KH
    Oncol Rep; 1999; 6(1):179-84. PubMed ID: 9864424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18.
    Mardirossian G; Brill AB; Harwood SJ; Olsen J; Dwyer KA; Siegel JA
    J Nucl Med; 1998 Apr; 39(4):671-6. PubMed ID: 9544680
    [No Abstract]   [Full Text] [Related]  

  • 31. Minimal residual disease: a target for radioimmunotherapy with 131I-labeled monoclonal antibodies? Some dosimetric considerations.
    Sautter-Bihl ML; Herbold G; Bihl H
    Recent Results Cancer Res; 1996; 141():67-75. PubMed ID: 8722420
    [No Abstract]   [Full Text] [Related]  

  • 32. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
    J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts.
    Molthoff CF; Pinedo HM; Schlüper HM; Rutgers DH; Boven E
    Int J Cancer; 1992 Apr; 51(1):108-15. PubMed ID: 1563830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
    Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
    Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
    Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH
    Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.
    Denardo SJ; O'Grady LF; Richman CM; Goldstein DS; O'Donnell RT; Denardo DA; Kroger LA; Lamborn KR; Hellström KE; Hellström I; Denardo GL
    Anticancer Res; 1997; 17(3B):1745-51. PubMed ID: 9179228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.